SlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016RNAi therapeutics for chronic HBV - Animal models (English) | Dr. Bruce D. GivenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016RNAi therapeutics for chronic HBV - Animal models (Chinese) | Dr. Bruce D. GivenView Slideset
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)SlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016New Treatments/Targets in HBV (Chinese) | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)SlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016New Treatments/Targets in HBV (English) | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016Hepatitis B immunological pathogenesis and immunological assessment | Dr. Chao WuView Slideset
BCBonaventura ClotetMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016Eradication of HIV (English) | Bonaventura Clotet, MD, PhDView Slideset
BCBonaventura ClotetMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016Eradication of HIV (Chinese) | Bonaventura Clotet, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016Selecting the best ART for each patient (Chinese) | Corklin Steinhart, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAsian Conference on Hepatitis and AIDS (ACHA) 2016Selecting the best ART for each patient (English) | Corklin Steinhart, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016(Abstract) Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population | Dr. R. EhretView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016(Abstract) Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine single tablet regimen | Dr. D. Di CarloView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2016(Abstract) Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects | Dr. G. SterrantinoView Slideset
